Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Precision Biosciences
DTIL · NASDAQ · Biological Products, (No Diagnostic Substances)
Precision Biosciences (DTIL) · oqro.io/stocks/DTIL · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
A Precision Biosciences officer told the SEC about a plan to sell $28K of Precision Biosciences shares around Nov 10, 2026. The shares were not acquired as compensation. That is a tiny part of all Precision Biosciences shares.
Since the trade +19.0% · S&P 500 −10.6% · to Nov 20
Bought 33% below the 52-week high, RSI 34, 20 points behind the S&P 500 over 3 months
A Precision Biosciences director paid $16K out of pocket for Precision Biosciences shares. 2 other people at Precision Biosciences bought some too, in the same month. It was the first purchase in 9 months.
Since the trade +19.0% · S&P 500 −10.6% · to Nov 20
Bought 33% below the 52-week high, RSI 34, 20 points behind the S&P 500 over 3 months
A Precision Biosciences director paid $7.1K out of pocket for Precision Biosciences shares. 2 other people at Precision Biosciences bought some too, in the same month. It was the first purchase in 9 months.
Since the trade +54.2% · S&P 500 +1.3% · to Nov 20
Bought 44% below the 52-week high, RSI 40, 7% under its 200-day average
A Precision Biosciences director paid $6.9K out of pocket for Precision Biosciences shares. 2 other people at Precision Biosciences bought some too, in the same month. Shares held went up 6% with this purchase.
Since the trade +52.3% · S&P 500 +3.4% · to Nov 20
A Precision Biosciences director paid $6.8K out of pocket for Precision Biosciences shares. 1 other person at Precision Biosciences bought some too, in the same month. Shares held went up 7% with this purchase.
Since the trade +74.5% · S&P 500 +13.6% · to Nov 20
A Precision Biosciences director paid $21K out of pocket for Precision Biosciences shares. 1 other person at Precision Biosciences bought some too, in the same month. Shares held went up 22% with this purchase.
Since the trade +74.5% · S&P 500 +13.6% · to Nov 20
A Precision Biosciences director paid $7K out of pocket for Precision Biosciences shares. 1 other person at Precision Biosciences bought some too, in the same month. Shares held went up 9% with this purchase.
Since the trade +63.4% · S&P 500 +21.3% · to Nov 20
A Precision Biosciences director paid $21K out of pocket for Precision Biosciences shares. 2 other people at Precision Biosciences bought some too, in the same month. Shares held went up 52% with this purchase.
Since the trade +63.4% · S&P 500 +21.3% · to Nov 20
A Precision Biosciences director paid $8.7K out of pocket for Precision Biosciences shares. 2 other people at Precision Biosciences bought some too, in the same month. Shares held went up 26% with this purchase.
Since the trade +45.4% · S&P 500 +19.9% · to Nov 20
A Precision Biosciences director paid $17K out of pocket for Precision Biosciences shares. 2 other people at Precision Biosciences bought some too, in the same month. Shares held went up 42% with this purchase.
Since the trade +73.7% · S&P 500 +17.3% · to Nov 20
A Precision Biosciences director paid $16K out of pocket for Precision Biosciences shares. 3 other people at Precision Biosciences bought some too, in the same month. Shares held went up 86% with this purchase.
Since the trade +59.1% · S&P 500 +15.9% · to Nov 20
A Precision Biosciences director paid $21K out of pocket for Precision Biosciences shares. 3 other people at Precision Biosciences bought some too, in the same month. Shares held went up 98% with this purchase.
Since the trade +59.1% · S&P 500 +15.9% · to Nov 20
The CFO of Precision Biosciences paid $10K out of pocket for Precision Biosciences shares. 3 other people at Precision Biosciences bought some too, in the same month. Shares held went up 6% with this purchase.
Since the trade +56.6% · S&P 500 +14.7% · to Nov 20
A Precision Biosciences director paid $14K out of pocket for Precision Biosciences shares. 3 other people at Precision Biosciences bought some too, in the same month. Shares held went up 72% with this purchase.
Since the trade +13.8% · S&P 500 +16.2% · to Nov 20
The CFO of Precision Biosciences paid $20K out of pocket for Precision Biosciences shares. It was the first purchase in over a year. Shares held went up 9% with this purchase.
A Precision Biosciences director paid $6K out of pocket for Precision Biosciences shares. 2 other people at Precision Biosciences bought some too, in the same month. It was the first purchase in 9 months.
A Precision Biosciences director paid $13K out of pocket for Precision Biosciences shares. 2 other people at Precision Biosciences bought some too, in the same month. Shares held went up 16% with this purchase.
A Precision Biosciences director paid $14K out of pocket for Precision Biosciences shares. 2 other people at Precision Biosciences bought some too, in the same month. Shares held went up 14% with this purchase.
A Precision Biosciences director paid $13K out of pocket for Precision Biosciences shares. 1 other person at Precision Biosciences bought some too, in the same month. Shares held went up 19% with this purchase.
3 open-market purchases and 5 open-market sales by insiders of DTIL between Feb 10, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 3, 2026. The data provider lists the next release for Mar 10, 2027; that date may change.
PurchaseSale30 days before a release30 days after
Trades in the 30 days around each of the last earnings releases
Dario Scimeca, Chief Legal Officer, Nov 10, 2026, about $28K. Sold 7 days after the company's previous earnings release on 2026-11-03Form 4
Stanley Frankel, Director, Sep 28, 2026, about $6K. Bought 36 days before the company's next earnings release on 2026-11-03Form 4
Melinda Brown, Director, Sep 25, 2026, about $7.1K. Bought 39 days before the company's next earnings release on 2026-11-03Form 4
Geno J Germano, Director, Sep 25, 2026, about $16K. Bought 39 days before the company's next earnings release on 2026-11-03Form 4
, President and CEO, Feb 18, 2026, about $79K. Sold 22 days before the company's next earnings release on 2026-03-12
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies